AKT1 and Obesity: Finally, potential therapeutic drugs were analysed based on pathways in PCC6, and alsterpaullone (cyclin-dependent kinase inhibitor) (Watanabe et al., 2020), orlistat (anti-obesity drug) (Yang et al., 2010), moxonidine (a selective imidazoline/alpha2 adrenergic receptor agonist) (Molderings et al., 2003), nalidixic acid (topoisomerase II inhibitors) (Nyce, 1989), and LY-294002 (PI3K/AKT inhibitor) (Chen et al., 2018) were proposed as C10-targeting pharmaceuticals in MM (Figure 5D).